Accelerating compliance
and approvals with unmatched regulatory insight and experience.

Contact Us Today
The Lachman Difference

The most efficient services.
The most qualified professionals.

Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA consultants and industry experts has offered compliance, regulatory affairs, and science & technology services to clients around the world.

Learn More About Us

Stay in the know

Sign up today for the Lachman Consultants blog.

Get the latest news on industry compliance, regulatory affairs, technical services, and a whole lot more.

    AREAS SERVED BY LACHMAN CONSULTANTS

    ADVANCE. CONFIDENTLY.

    As long-standing leaders in technical and regulatory consulting services, Lachman Consultants provides both experience and excellence through an unmatched team of respected industry professionals and SMEs.

    Mock FDA Audits

    Are you fully prepared for an inspection at your facility?

    Our team of experienced ex-FDA investigators offer comprehensive Mock FDA Audit services to help you prepare for an actual FDA inspection. Our team of experts will conduct a thorough inspection of your facility, review your documentation, and provide you with valuable feedback on areas that need improvement to ensure compliance with FDA regulations – both remotely and on-site.

    Learn More About Mock FDA Audits

    OnCall Image

    Recent Posts

    The Lachman Consultants Blog

    The latest on industry compliance, regulatory affairs, technical services, and a whole lot more.

    FDA Publishes 4th Quarter FY 2026 Mean and Median ANDA Approval Times

    FDA Publishes 4th Quarter FY 2026 Mean and Median ANDA Approval Times

    This morning, the FDA updated its Generic Drugs Program Monthly and Qu...
    Read More
    FDA Does Some Clean Up Regarding Discontinued Reference Listed Drug Products

    FDA Does Some Clean Up Regarding Discontinued Reference Listed Drug Products

    If a reference listed drug (RLD) upon which an ANDA sponsor relies as ...
    Read More
    GPL-1 Rare but Serious Eye Condition Warrants Safety Label Changes

    GLP-1 Rare but Serious Eye Condition Warrants Safety Label Changes

    All drugs have risks. May of those risks show up in the clinical studi...
    Read More

    OGD Posts Final FY 2026 Statistics

    While the charts on the Generic Drugs Program Monthly and Quarterly Ac...
    Read More

    GRx+Biosims 2026 Is in the Books – Let’s Talk About Exclusivity and Other Issues

    One of the most consistent themes discussed throughout the Association...
    Read More
    Unofficial October 2026 ANDA Approval Actions and More on FY 2026

    Unofficial October 2026 ANDA Approval Actions and More on FY 2026

    The first month of the new FY was (unfortunately) a slow start out of ...
    Read More
    ADVANCE CONFIDENTLY
    Contact Us Today